JP2021518111A5 - - Google Patents
Info
- Publication number
- JP2021518111A5 JP2021518111A5 JP2020549002A JP2020549002A JP2021518111A5 JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5 JP 2020549002 A JP2020549002 A JP 2020549002A JP 2020549002 A JP2020549002 A JP 2020549002A JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- nucleic acid
- cell
- amino acid
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114641A JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643139P | 2018-03-14 | 2018-03-14 | |
| US62/643,139 | 2018-03-14 | ||
| PCT/US2019/021833 WO2019178085A1 (en) | 2018-03-14 | 2019-03-12 | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Division JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518111A JP2021518111A (ja) | 2021-08-02 |
| JP2021518111A5 true JP2021518111A5 (cg-RX-API-DMAC7.html) | 2022-03-18 |
| JP7314161B2 JP7314161B2 (ja) | 2023-07-25 |
Family
ID=67907266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549002A Active JP7314161B2 (ja) | 2018-03-14 | 2019-03-12 | ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法 |
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12606603B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3765487A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7314161B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260021083A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112088165A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019234580B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020018534A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3093791A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202091984A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL277268A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020009464A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202008926RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019178085A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7438123B2 (ja) | 2018-03-14 | 2024-02-26 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体 |
| US20260151429A1 (en) * | 2022-08-25 | 2026-06-04 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| SG186017A1 (en) | 2007-11-30 | 2012-12-28 | Kalobios Pharmaceuticals Inc | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープCity of Hope | 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt) |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| KR101763499B1 (ko) | 2012-11-07 | 2017-07-31 | 화이자 인코포레이티드 | 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체 |
| EP2929045B1 (en) | 2012-12-05 | 2020-12-02 | SOLA Biosciences LLC | Protein expression enhancing polypeptides |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| ES2738705T3 (es) | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| EP3250609A4 (en) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
| HK1256130A1 (zh) | 2015-07-21 | 2019-09-13 | City Of Hope | 用於嵌合抗原受体和其他受体的表达的t细胞 |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| JP7189019B2 (ja) * | 2016-02-05 | 2022-12-13 | シティ・オブ・ホープ | 中枢神経系の癌の治療のための操作されたt細胞の投与 |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| JP7295795B2 (ja) | 2016-07-29 | 2023-06-21 | ジュノー セラピューティクス インコーポレイテッド | 免疫調節ポリペプチドならびに関連する組成物および方法 |
| CA3039136A1 (en) | 2016-09-02 | 2018-03-08 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| US12083148B2 (en) | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| JP7438123B2 (ja) | 2018-03-14 | 2024-02-26 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体 |
-
2019
- 2019-03-12 WO PCT/US2019/021833 patent/WO2019178085A1/en not_active Ceased
- 2019-03-12 US US16/979,475 patent/US12606603B2/en active Active
- 2019-03-12 CN CN201980030021.9A patent/CN112088165A/zh active Pending
- 2019-03-12 EP EP19767433.6A patent/EP3765487A4/en not_active Withdrawn
- 2019-03-12 KR KR1020267001996A patent/KR20260021083A/ko active Pending
- 2019-03-12 KR KR1020207028968A patent/KR102917671B1/ko active Active
- 2019-03-12 AU AU2019234580A patent/AU2019234580B2/en active Active
- 2019-03-12 EP EP24214241.2A patent/EP4491718A3/en active Pending
- 2019-03-12 EA EA202091984A patent/EA202091984A1/ru unknown
- 2019-03-12 JP JP2020549002A patent/JP7314161B2/ja active Active
- 2019-03-12 SG SG11202008926RA patent/SG11202008926RA/en unknown
- 2019-03-12 MX MX2020009464A patent/MX2020009464A/es unknown
- 2019-03-12 CA CA3093791A patent/CA3093791A1/en active Pending
- 2019-03-12 BR BR112020018534-5A patent/BR112020018534A2/pt not_active Application Discontinuation
-
2020
- 2020-09-10 IL IL277268A patent/IL277268A/en unknown
- 2020-09-10 MX MX2025010440A patent/MX2025010440A/es unknown
-
2023
- 2023-07-12 JP JP2023114641A patent/JP7696958B2/ja active Active
-
2024
- 2024-04-24 AU AU2024202681A patent/AU2024202681A1/en active Pending
-
2026
- 2026-03-17 US US19/569,793 patent/US20260184753A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518108A5 (cg-RX-API-DMAC7.html) | ||
| US20250043013A1 (en) | Nucleic acids encoding il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy | |
| JP6543626B2 (ja) | 多部分シグナル伝達タンパク質およびその使用 | |
| EP3445847B1 (en) | Immunomodulatory il2r fusion proteins and uses thereof | |
| US20170292118A1 (en) | Method for modulating car-induced immune cells activity | |
| JP7696958B2 (ja) | ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法 | |
| EP4382119A1 (en) | A kit for use in the treatment of hematological cancer | |
| JP2025540251A (ja) | 血液癌の治療において使用するためのキット | |
| WO2023102109A1 (en) | Ex vivo cytokine priming strategies for preparing activated cd26-high immune cells and uses in cancer therapies | |
| JP2023529443A (ja) | 抗cd171キメラ抗原受容体 | |
| KR20260032682A (ko) | 두경부암 치료를 위한 egfr을 표적으로 하는 키메라항원 수용체 및 이를 발현하는 t 세포 치료제 |